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A B S T R A C T
Parkinson's disease (PD) is a progressive neurological disorder that has no reliable biomarkers. The aim of this
study was to explore the potential of semi-automated sub-regional analysis of the striatum with magnetic re-
sonance imaging (MRI) to distinguish PD patients from controls (i.e., as a diagnostic biomarker) and to compare
PD patients at different stages of disease.
With 3 Tesla MRI, diffusion- and T1-weighted scans were obtained on two occasions in 24 PD patients and 18
age-matched, healthy controls. PD patients completed one session on and the other session off dopaminergic
medication. The striatum was parcellated into seven functionally disparate sub-regions. The segmentation was
guided by reciprocal connections to distinct cortical regions. Volume, surface-based morphometry, and integrity
of white matter connections were calculated for each striatal sub-region.
Test-retest reliability of our volume, morphometry, and white matter integrity measures across scans was
high, with correlations ranging from r= 0.452, p < 0.05 and r=0.985, p < 0.001. Global measures of
striatum such as total striatum, nucleus accumbens, caudate nuclei, and putamen were not significantly different
between PD patients and controls, indicating poor sensitivity of these measures, which average across sub-
regions that are functionally heterogeneous and differentially affected by PD, to act as diagnostic biomarkers.
Further, these measures did not correlate significantly with disease severity, challenging their potential to serve
as progression biomarkers. In contrast, a) decreased volume and b) inward surface displacement of caudal-motor
striatumethe region first and most dopamine depleted in PDedistinguished PD patients from controls. Integrity
of white matter cortico-striatal connections in caudal-motor and adjacent striatal sub-regions (i.e., executive and
temporal striatum) was reduced for PD patients relative to controls. Finally, volume of limbic striatum, the only
striatal sub-region innervated by the later-degenerating ventral tegmental area in PD, was reduced in later-stage
compared to early stage PD patients a potential progression biomarker.
Segmenting striatum based on distinct cortical connectivity provided highly sensitive MRI measures for di-
agnosing and staging PD.
1. Introduction
Parkinson's disease (PD) is a neurodegenerative condition, affecting
1% of people aged 65 or older in industrialized countries (Goldman &
Postuma, 2014), characterized by disabling motor and non-motor
symptoms. Though dopamine-replacement medications treat motor
symptoms early in PD, later in disease, these therapies are less effective,
whereas other symptoms are not dopamine-responsive at all (Poewe
et al., 2010). There are no cures or disease-modifying therapies (Emre,
2015). The inadequate state of current therapy urgently requires
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correction. The development of sensitive and reliable biomarkers is
critical to aid in the diagnosis of PD and to measure the efficacy of new
treatments aiming to slow, halt, or reverse PD (Tuite, 2016; Miller &
O'Callaghan, 2015). Diagnostic biomarkers that distinguish PD patients
from healthy controls will improve the appropriate enrollment of pa-
tients in clinical trials. Progression biomarkers that objectively track
disease evolution are needed to act as endpoints for critical tests of
potential treatments. Prevention or delay of disease progression can
only be ascertained if these objective endpoints are available. Clinical
response alone is an insufficient measure that is subjective and con-
founds symptom-alleviating with disease-altering impacts (Strimbu &
Tavel, 2010).
Magnetic resonance imaging (MRI) offers substantial promise to
provide biomarkers of PD. There have been advances in determining
potential structural (Rahmim et al., 2017; Sulzer et al., 2018; Sierra
et al., 2017; Guan et al., 2017; Saeed et al., 2017) and functional (Saeed
et al., 2017; Tang et al., 2017) biomarkers, such as differential dopa-
mine transporter expression (Rahmim et al., 2017; Sierra et al., 2017)
and mapping of iron deposition in the dopaminergic midbrain (Sulzer
et al., 2018; Guan et al., 2017). Despite early promise, this literature is
still in its infancy. Most of these studies fail to include a measure of test-
retest reliability of the scanning protocol. Further, recent reviews of
structural (Saeed et al., 2017; Mak et al., 2015; Al-Radaideh & Rababah,
2016; Yang et al., 2018; Guimaraes et al., 2018), and functional (Miller
& O'Callaghan, 2015; Tahmasian et al., 2015; Weingarten et al., 2015)
neuroimaging in PD reveal few consistent patterns. Most unexpectedly,
structural abnormalities in the striatum, the most dopamine-depleted
brain region in PD and the region that mediates the cardinal motor
manifestations, are not consistent (Politis, 2014; Pyatigorskaya et al.,
2014), requiring large numbers of participants (Tuite, 2016; Hopes
et al., 2016; Lewis et al., 2016), though biomarkers ultimately need to
be sensitive at even the single-subject level. The clinical role of neu-
roimaging in PD is poorly developed.
The striatum can be subdivided in a number of ways. Typically, it is
divided into the nucleus accumbens, the caudate nuclei, and the pu-
tamen because these are separable at a gross level of inspection. This
division, however, does not respect important differences in dopamine
supply. Segmenting the striatum into its ventral (i.e., VS) and dorsal
(i.e., DS) aspects separates these structures on the basis of different
dopaminergic inputs. The VS, comprising the nucleus accumbens and
most ventral parts of caudate nuclei and putamen, receives dopamine
from the ventral tegmental area (VTA; Kish et al., 1988) whereas the
DS, including the bulk of the caudate nuclei and the putamen, is sup-
plied with dopamine from the substantia nigra pars compacta (SNc)
(Kish et al., 1988). This distinction is important as the VTA degenerates
later and less in PD than the SNc (Hornykiewicz, 1998; Alberico et al.,
2015). Even within the SNc-innervated DS, segments of striatum are
predicted to be dopamine-deprived to varying extents and at different
times in PD. The cardinal motor symptoms of PD arise when the loss of
dopamine-producing cells in SNc is sufficient to seriously restrict do-
paminergic input to the caudal-motor segment of the DS (Kish et al.,
1988; Fearnley & Lees, 1991; McRitchie et al., 1997). The caudal-motor
segment consists of the dorsal, caudal putamen, and is the region that is
presumed to be first and most dopamine depleted in PD.
In addition to these expected disparities in dopamine innervation,
sub-regions of the striatum receive glutamatergic projections from
distinct cortical regions that account for functional differences across
these sub-regions.
Structural measurement of total striatum, nucleus accumbens, cau-
date nuclei, or putamen involves averaging across regions that differ in
their dopamine-depletion and functions, potentially accounting for the
insensitivity of structural measures of the striatum to differentiate PD
patients from controls to date. Further, this might explain why esti-
mates of total striatal volume or shape (i.e., morphology) are unreliable
across studies that include samples of PD patients who differ in PD
stage, severity, and subtype. The expected evolution of dopamine de-
nervation across regions of the striatum in PD, based on pathological
studies, coupled with the increasing understanding of the functional
heterogeneity across sub-regions of the striatum presents a clear bio-
logical motive to pursue sub-regional analysis of the striatum. This
understanding suggests that changes in volume and shape of distinct
sub-regions of the striatum could provide a) sensitive and reliable
biomarkers of PD and its progression, as well as b) an explanation for
symptoms that emerge at different disease stages. To our knowledge,
this type of analysis has never previously been applied to PD.
1.1. Current study
A specific aim of the current study was to explore the potential of
sub-regional analysis of the striatum to distinguish PD patients from
controls as well as to distinguish patients at different stages of PD. We
implemented an MRI segmentation proposed by Tziortzi et al. (2011;
2014). This segmentation was informed by a meta-analysis of func-
tional MRI (fMRI) studies and guided by cortical regions to which
distinct sub-regions of striatum are reciprocally connected. The pro-
posed parcellation divides the striatum into seven sub-regions: caudal-
motor, limbic, rostral-motor, executive, parietal, occipital, and tem-
poral regions, based on reciprocally connected cortical regions
(Fig. 1A).
The caudal-motor striatum is defined by its reciprocal connections to
the primary motor and premotor cortices, comprising the caudal pu-
tamen and a small segment of anterior dorsal caudate. The caudal-
motor striatal sub-region includes the segment that is presumed first
and most dopamine-depleted in PD (Kish et al., 1988; Fearnley & Lees,
1991; McRitchie et al., 1997). Dopaminergic denervation of this sub-
region causes motor symptoms, prompting PD diagnosis, and should
therefore be affected in all PD patients, regardless of disease stage. We
therefore predict that measures of caudal-motor striatum will be most
sensitive to PD versus control group differences and hence will have
highest diagnostic value. The limbic striatum, receiving cortical input
from medial and ventral prefrontal regions, such as the orbitofrontal
cortex, comprises the nucleus accumbens and ventral caudate and pu-
tamen, essentially constituting the VS. This limbic striatal subdivision is
also very important in PD as it represents the only portion of striatum
that is innervated by VTA. It is contended that VTA is relatively spared
compared to SNc, especially in early PD (Kish et al., 1988;
Hornykiewicz, 1998). In this way, limbic striatal measures are expected
to be most differentially impacted by disease stage. We therefore expect
that measures of limbic striatum have greatest potential to act as bio-
markers of disease progression. Contrasting the effect of disease stage
on structural measures of limbic striatum relative to other SNc-in-
nervated portions of striatum provides a clear opportunity to test pro-
posals regarding the pathophysiology of disease progression in PD that
are widely accepted (Nyberg et al., 2015; Dean 3rd et al., 2016).
In the current study, we contrasted a sample of PD patients and
healthy controls on a) global volumes of striatum, caudate nuclei, pu-
tamen, and nucleus accumbens, versus b) volume, shape, and con-
nectivity of the seven striatal sub-regions segmented based on their
cortical connectivity and function as suggested by Tziortzi et al. (2011;
2014). Within our PD sample, we further investigated whether striatal
sub-regional volumes correlated with disease progression, estimated
with the motor sub-scale of the Unified Parkinson's Disease Rating Scale
(UPDRS-III).
A biomarker of PD must be test-retest reliable. An important addi-
tional aim of the current study was to investigate the test-retest relia-
bility of our proposed structural measures and analysis approaches.
Toward this end, structural MRIs were obtained from PD patients and
controls on two occasions separated by no more than one week. In this
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way, differences in our structural estimates across occasions could owe
only to measurement error.
2. Methods
2.1. Participants
Twenty-four PD patients and 18 healthy, age- and education-mat-
ched controls completed the study. All participants with PD were pre-
viously diagnosed by a licensed neurologist, had no co-existing diag-
nosis of dementia or another neurological or psychiatric disease, save
for mild depression or anxiety. All PD patients met the core assessment
criteria for surgical interventional therapy and the UK Brain Bank cri-
teria for the diagnosis of idiopathic PD (Hughes et al., 1992). All PD and
no control participants were treated with dopaminergic therapy.
Healthy controls were required to be within 5 years of age and of
education to the PD patient to whom they were matched (see Table 1).
Participants with PD were recruited through a movement disorders
database at the London Health Sciences Centre. Participants abusing
alcohol, prescription or illicit drugs, or taking cognitive-enhancing
medications including donepezil, galantamine, rivastigmine, meman-
tine, or methylphenidate were excluded from participating, as were
patients who were diagnosed before the age of 45, had more than two
first-degree relatives with PD, or had contraindication to MRI. No
participants in this study were diagnosed with dementia or an impulse
control disorder.
Fig. 1. Visualization of A) the connectivity-based sub-regional parcellation of the striatum for controls and PD patients, and B) the connected white matter tracts
between sub-regions and the cortex (control subjects).
Table 1
Demographic and clinical screening measures for PD patients and controls ON
and OFF medication.
Group PD Control p-value
n 24 18
Age 68.12 (1.10) 66.06 (2.12) 0.355
Education 15.94 (0.62) 15.76 (1.09) 0.877
Age of Onset 61.64 (1.39)
Duration 6.48 (0.74) –
LED 600.32 (59.32) –
DA 11 –
H & Y 2.52 (0.02) –
UPDRS-III OFF 19.03 (1.00) 0.15 (0.12) <0.001
ON 16.03 (1.06) –
BDI-II OFF 8.09 (1.16) 2.44 (0.70) 0.001
ON 8.33 (1.31) 2.50 (0.67) 0.001
BAI-I OFF 7.38 (1.48) 1.72 (0.48) 0.003
ON 8.19 (1.59) 2.61 (0.54) 0.006
ANART 123.57 (1.45) 123.90 (1.80) 0.892
MOCA 27.40 (0.32) 28.22 (0.37) 0.123
Values are reported as mean (± SEM). P-values measure the significance of the
between group differences in each relevant category. LED= ι-dopa equivalence
dose (mg/daily); DA=Number of individuals prescribed a dopamine agonist;
H & Y=Hoehn and Yahr scale score; UPDRS-III =Unified Parkinson's Disease
Rating Scale – Motor sub-scale; BDI-II= Beck Depression Inventory II; BAI-
I= Beck Anxiety Inventory I; ANART=American Adult National Reading Test
estimate of verbal IQ; MOCA=Montreal Cognitive Assessment. Patients with
PD completed the ANART and MOCA on medication regardless of medication
order.
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2.2. Procedures
The UPDRS-III and Hoehn and Yahr scale was scored by a licensed
neurologist with sub-specialty training in movement disorders (PAM) to
assess the presence and severity of motor symptoms for all patients both
on and off dopaminergic medication. Control participants were also
screened with the UPDRS-III to rule out undiagnosed neurological illness.
Mean group demographics, as well as cognitive and affective screening
scores for all patients and controls in each experimental group were re-
corded (Table 1). For PD patients, duration of disease and daily doses of
dopamine replacement therapy in terms of ι-3,4-dihydroxyphenylalanine
(ι-dopa) equivalents were calculated and presented in Table 1. Calcula-
tion of daily ι-dopa equivalent dose (LED) for each patient was based on
the theoretical equivalence to ι-dopa as follows: ι-dopa dose
(mg)×1+ ι-dopa controlled release (mg)×0.75+ ι-dopa (mg)×1/3
if on entacapone+amantadine (mg)×1+apomorphine
(mg)×10+bromocriptine (mg)×10+pergolide (mg)×100+pra-
mipexole as salt (mg)×67+ rasagiline (mg)×100+ ropinirole
(mg)×20+ selegiline (mg)×10 (Tomlinson et al., 2010).
All participants completed two MRI sessions. PD patients performed
one session on and the other off dopaminergic medication. During ON
testing sessions, PD patients took their dopaminergic therapy as pre-
scribed by their treating neurologist. During OFF testing sessions, PD
patients abstained from taking all dopaminergic medications including:
dopamine precursors such as ι-dopa, aromatic-L-amino-acid decarbox-
ylase inhibitors such as carbidopa, and catechol-O-methyltransferase
(COMT) inhibitors such as entacapone for a minimum of 12 to a max-
imum of 18 h, and dopamine agonists, such as pramipexole, ropinirole
or pergolide, as well as amantadine, rasagiline, and selegiline for 16 to
20 h before beginning OFF testing sessions. All patients confirmed that
they complied with these instructions. UPDRS-III was performed for
further confirmation. The ON-OFF order was counterbalanced across
participants and though healthy controls did not take dopaminergic
therapy during any session, their sessions were labelled as ON-OFF to
correspond to the order of the PD patient to whom they were matched.
Matching was performed at time of testing, prior to data analysis. This
controlled for possible order, fatigue, and practice effects.
All participants provided informed written consent to the protocol
before beginning the experiment, according to the Declaration of
Helsinki (2013). All participants with PD were competent and had the
capacity to provide informed consent. This study was approved by the
Health Sciences Research Ethics Board of the University of Western
Ontario.
2.2.1. Image analysis overview
T1-weighted structural images as well as a DTI series were collected
twice for each participant. Structural images were processed to segment
the striatum, and to parcellate sub-regions based on cortical con-
nectivity. A surface-based framework was used to measure local
striatum deformations and connected white matter integrity, with all
measurements taken on points that share correspondence to a common
striatum surface template. Briefly, the steps taken to achieve this were
to 1) segment the striatum and cortical regions using an atlas-based
approach, 2) generate a canonical surface template (Fig. 2A) and fit it to
each participant's striatum (Fig. 2B), and 3) employ these warped
templates to perform surface-based tractography and morphometry
(Fig. 2C). Maximum connectivity parcellations for each participant
were calculated to generate participant-specific estimates of striatal
surface area connected to each cortical region. These were then aver-
aged across participants to generate a common parcellation map to
summarize regional metrics of connected white matter integrity (i.e.,
fractional anisotropy; FA), and local surface morphometry for later
estimating inward and outward displacement for individual partici-
pants (Fig. 2D).
2.2.2. Structural MRI acquisition
ON and OFF scanning sessions were identical. MRI scanning took
place at the Robarts Research Institute at the University of Western
Ontario on a Siemens Prisma Fit 3T scanner. A scout image for posi-
tioning the participant was first obtained. This was followed by a
magnetization-prepared rapid acquisition with gradient echo
(MPRAGE) sagittal T1-weighted scan with the following parameters;
repetition time (TR)= 2300ms; echo time (TE)= 2.98ms; flip
angle= 9°; matrix size= 256×256 pixels; and with one whole brain
image consisted of 192, 1mm-thick slices. The field of view was or-
iented along the anterior and posterior commissure with a matrix of
256× 256 pixels, an isotropic voxel size of 1×1×1mm3. A diffu-
sion-weighted echo-planar imaging (DWI) series (gradient direc-
tions= 64, b-value=1000 s/mm2, isometric voxel size of 2mm, ma-
trix size of 128× 128 pixels) was also acquired in each session in PD
patients and controls.
2.2.3. T1 and DWI pre-processing
Structural and diffusion images were first imported into NIFTI vo-
lumes using dcm2niix. Pre-processing of the T1-weighted image in-
cluded skull-stripping (FSL BET), non-uniformity correction (N4), and
intensity normalization. The DWI pre-processing included linear regis-
tration to the b0 image (FSL eddy correct), skull-stripping (FSL BET),
co-registration to the T1-weighted image (NiftyReg), tensor fitting (FSL
dtifit), and fibre modelling for probabilistic ball and stick tractography
(FSL BEDPOST). Processing was carried out using in-house and openly
available image processing scripts (https://github.com/khanlab/
diffparc-sumo). Quality assurance was verified at each stage of the pi-
pelines using generated overlay images, with registration failures cor-
rected using alternative initialization parameters.
2.2.4. Atlas-based segmentation
Structural striatum labels (caudate, putamen, VS, and a probabilistic
labelling of the entire striatum) were obtained from the MNI152 1mm
atlas supplied with FSL (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Atlases/
striatumstruc), and cortical target regions were adapted from the
Harvard-Oxford FSL atlas. The cortical target region labelling on the
MNI152 1mm atlas was based on the Tziortzi et al. (2011; 2014)
striatal connectivity atlas, and consisted of caudal-motor, limbic, ros-
tral-motor, executive, parietal, occipital, and temporal regions, as de-
scribed earlier. Atlas-based segmentation of each participant was per-
formed using the NiftyReg linear and deformable b-spline registration
tools (Modat et al., 2014; Modat et al., 2010). Volumes of the striatum
sub-region labels, caudate, putamen, VS were extracted from the au-
tomated segmentations. Once again, quality assurance for each regis-
tration was performed, and failures in linear registration were corrected
by initialization with an alternate subject transformation matrix.
2.2.5. Canonical surface template generation and fitting
The probabilistic labels of the entire striatum in each participant
were transformed back to the MNI space using obtained linear trans-
formations, and these images, linearly aligned in the MNI space, were
used to generate an unbiased average for surface generation. The large
deformation diffeomorphic metric mapping (LDDMM) registration al-
gorithm was used to generate the average, by alternating steps of
template generation through averaging, and registration of each seg-
mentation image to this template. The resulting probabilistic segmen-
tation was then used to generate our striatum template surface through
an isosurface at 50% probability. To provide point-wise correspondence
between all striatum surfaces, the 3D volume of the template striatum
was then fit to each participant's striatum segmentation using LDDMM,
with affine initialization. The template surface was then propagated to
each participant striatum, as well as the striatum in native DWI space,
to provide surfaces with common indices for performing morphometry
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and tractography. For surface morphometry, displacements at each
point were computed between the template surface and the injected
participant surface, using the projection along the surface normal to
quantify a scalar inward/outward distance. To account for any local
misalignment between the template and participant striatum surfaces,
the mean displacement across a spherical neighbourhood (10mm ra-
dius) was computed for each point and subtracted from the local point-
wise displacement.
2.2.6. Tractography
Probabilistic multi-fibre tractography was performed using FSL
BEDPOST (Behrens et al., 2003; Behrens et al., 2007) with the surface
vertices of the striatum used as seed points. Surface meshes in VTK file
format were converted to GIFTI for input into FSL BEDPOST, and 5000
seeds were initiated from each surface point. The paths taken from each
point were retained and used to generate connected white-matter
probability maps for sampling the FA of white matter connected to each
point. Subject-specific connectivity parcellations of the striatum were
created by assigning a numerical label to each surface point, based on
the cortical target, out of seven possible targets, with maximal con-
nection probability lateralized based on left and right striatum in the
template, to provide a labelling of 14 regions. Tractography was also
performed from all striatum segmentation voxels, to generate subject-
specific volumetric parcellations, and these were linearly transformed
to the MNI space for statistical analysis.
2.2.7. Regional surface-based morphometry and white matter integrity
To ensure homologous striatal surface points are used when sum-
marizing morphometry and white matter integrity measurements, we
generated a group-average parcellation based on all control participants
in the study. This was done by majority voting. That is, we assign the
label at each point that is shared by the greatest number of control
participants. Surface-based inward/outward displacement measure-
ments were averaged across each of the 14 regions to quantify surface
morphometry. Similarly, the FA measurements were also averaged
across each connected white matter region to quantify white matter
integrity.
2.2.8. Output for statistical analysis
Group differences of normalized volume, surface displacement, and
FA measures for functional sub-regions of striatum were investigated. In
these analyses, normalized volume constituted a z-score for individual
participants' volume measures for each sub-region relative to the
overall average for that sub-region based on all participants in the
study. This number was then multiplied by the total number of voxels
contained within the striatum to yield the number of voxels in each
striatal sub-region. Surface displacement and FA were calculated as
described above and normalized relative to a group-average parcella-
tion based on all control participants.
2.2.9. Statistical analyses
PD patients were compared to healthy, age- and education-matched
controls. In subsequent analyses, PD patients were investigated for the
effect of disease stage on structural measures. In both the ON and OFF
sessions, we obtained and compared measures for PD and control par-
ticipants of a) total striatum, nucleus accumbens, caudate nucleus, and
putamen versus b) striatum segmented based on function into caudal-
motor, limbic, rostral-motor, executive, parietal, occipital, and tem-
poral striatal sub-regions as described above, according to the method
proposed by Tziortzi et al. (2011; 2014). For all analyses, bilateral
structural measures were combined and averaged to provide a single
estimate of region or sub-region, in each session. For all statistical
analyses, p < 0.05, corrected for multiple comparisons using Bonfer-
roni correction was used as our statistical threshold. Briefly, the cor-
rected p value was obtained by dividing the critical p value by seven
(i.e. the number of striatal sub-regions under investigation).
First, the test-retest reliability of all measures was investigated with
correlations between estimates obtained in the ON and OFF sessions
separately for PD patients and controls.
Next, total striatum volumes as well as volumes for each the nucleus
accumbens, caudate nuclei, and putamen were contrasted between PD
patients and healthy controls in independent sample t-tests.
Independent sample t-tests were performed on measures of volume,
surface displacement, and FA for each functional striatal sub-region,
comparing PD patients to healthy controls.
Fig. 2. Depiction of surface-based morphometry
procedure for a single subject, showing the A) ca-
nonical surface, generated from an average of all
subjects, B) the canonical surface warped to fit the
subject anatomy, C) these two surfaces shown over-
laid to highlight differences, and D) quantification of
differences between these surfaces using inward
(cool colours) and outward (warm colours) dis-
placement vectors. (For interpretation of the refer-
ences to color in this figure legend, the reader is
referred to the web version of this article.)
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Bayesian independent sample t-tests were conducted on all above
contrasts to investigate the strength of the frequentist results. BF10
values of less than three, commonly indicated to be the Bayesian cor-
ollary of p < 0.05 in frequentist hypothesis testing, indicates that the
results strongly support the null hypothesis. BF10 values greater than
three indicate that the results strongly support the alternative hypoth-
esis. Bayesian analyses are reported along with frequentist statistics.
Finally, within our PD group, we investigated the sensitivity of sub-
regional volume measures to disease stage. The dependent measures
were sub-regional volume and disease stage was estimated with
UPDRS-III in the OFF state.
3. Results
3.1. Demographic and clinical contrasts
There were no significant demographic or cognitive differences
between PD and control participants (Table 1). Participants with PD
scored significantly higher on both BDI II and BAI compared to controls.
No differences were found in terms of depressive or anxious symptoms
for PD patients or controls contrasting the ON and OFF sessions.
UPDRS-III scores were significantly higher in participants with PD
measured off relative to on dopaminergic medication, as expected.
UPDRS-III scores ranged from 10 to 25.5 for PD patients, with a mean
(± standard error of the mean; SEM) of 19.03 (± 1.00) off medication
and 16.03 (± 1.06) on medication, indicating a relatively broad range
of disease. PD patients varied in disease duration from 1 to 14 years
since diagnosis, with a mean (± SEM) of 6.48 (± 0.74) years. MoCA
scores ranged between 22 and 30, with mean (± SEM) of 27.74
(± 0.26).
3.2. Test-retest reliability
Correlations of volume estimates for total striatum, nucleus ac-
cumbens, putamen, and caudate nuclei for OFF and ON sessions were
highly significant. Similarly, volume, surface displacement, and FA
measures for caudal-motor, limbic, rostral-motor, executive, parietal,
occipital, and temporal striatal sub-regions for OFF and ON sessions
were highly significant (all pBonferroni < 0.01). The estimates,
Table 2
Striatal sub-region estimates, correlations, and significance values for OFF and ON medication for PD patients and controls.
Volume PD (n= 24) Control (n= 18)
OFF ON r p OFF ON r p
Total 19,296.4 (469.3) 18,974.1 (410.9) 0.819 *** 18,412.0 (480.1) 18,418.7 (465.8) 0.985 ***
Accumbens 2335.2 (99.9) 2347.2 (50.5) 0.652 ** 2237.9 (73.4) 2217.6 (67.9) 0.944 ***
Putamen 9346.8 (305.1) 9217.6 (212.7) 0.688 *** 8840.0 (181.1) 8891.7 (192.5) 0.981 ***
Caudate 7124.0 (254.5) 7146.8 (238.7) 0.521 * 7007.5 (264.5) 7002 (254.4) 0.984 ***
Caudal-motor 1546.2 (88.4) 1628.9 (99.4) 0.621 ** 1866.5 (110.5) 1772.8 (121.2) 0.575 *
Rostral-motor 1081.7 (118.1) 986.0 (108.5) 0.835 *** 1008.3 (120.7) 1139.7 (150.6) 0.929 ***
Executive 15,311.1 (551.8) 14,836.8 (455.5) 0.847 *** 13,976.2 (784.0) 14,109.6 (776.0) 0.961 ***
Limbic 1570.4 (151.9) 1659.7 (140.5) 0.610 ** 1504.4 (259.8) 1416.8 (239.4) 0.948 ***
Parietal 2041.6 (160.7) 2023.5 (121.8) 0.601 ** 2294.4 (126.9) 2223.0 (119.7) 0.662 **
Occipital 615.7 (54.3) 532.6 (60.1) 0.700 *** 589.1 (78.5) 593.3 (76.9) 0.893 ***
Temporal 604.9 (128.1) 575.3 (93.1) 0.452 * 664.5 (148.0) 700.5 (114.4) 0.598 **
Displacement PD Control
OFF ON r p OFF ON r p
Caudal-motor −0.654 (0.178) −0.679 (0.179) 0.985 *** −0.296 (0.74) −0.324 (0.069) 0.727 ***
Rostral-motor −0.691 (0.124) −0.660 (0.122) 0.831 *** −0.399 (0.088) −0.427 (0.085) 0.800 ***
Executive −0.077 (0.058) −0.089 (0.057) 0.964 *** 0.0488 (0.032) 0.037 (0.037) 0.948 ***
Limbic 0.758 (0.114) 0.816 (0.117) 0.891 *** 0.746 (0.142) 0.759 (0.144) 0.893 ***
Parietal −0.035 (0.058) −0.060 (0.069) 0.922 *** 0.009 (0.036) −0.001 (0.030) 0.767 ***
Occipital 0.416 (0.071) 0.401 (0.066) 0.812 *** 0.374 (0.069) 0.357 (0.068) 0.891 ***
Temporal 0.193 (0.131) 0.146 (0.136) 0.936 *** 0.322 (0.109) 0.307 (0.114) 0.980 ***
Fractional Anisotropy PD Control
OFF ON r p OFF ON r p
Caudal-motor 0.327 (0.009) 0.326 (0.008) 0.840 *** 0.348 (0.008) 0.352 (0.009) 0.863 ***
Rostral-motor 0.426 (0.006) 0.430 (0.006) 0.741 *** 0.420 (0.007) 0.423 (0.007) 0.921 ***
Executive 0.332 (0.004) 0.323 (0.005) 0.881 *** 0.339 (0.004) 0.340 (0.005) 0.827 ***
Limbic 0.335 (0.007) 0.327 (0.007) 0.645 ** 0.339 (0.007) 0.341 (0.008) 0.900 ***
Parietal 0.391 (0.004) 0.393 (0.004) 0.653 ** 0.390 (0.008) 0.385 (0.010) 0.924 ***
Occipital 0.437 (0.005) 0.440 (0.004) 0.697 *** 0.434 (0.009) 0.433 (0.009) 0.983 ***
Temporal 0.344 (0.005) 0.345 (0.004) 0.470 * 0.360 (0.005) 0.361 (0.005) 0.867 ***
Values are reported as mean (SEM). Volume, displacement and fractional anisotropy (FA) estimates are presented for both PD patients and controls, off and on
medication. Pearson correlation coefficients (r) between on and off sessions are presented, along with the corresponding significance (p) value, corrected for multiple
comparisons using Bonferroni correction. ***p < 0.001, **p < 0.01, *p < 0.05.
Fig. 3. Mean normalized volume of caudal-motor sub-region in mm3 for PD
patients and controls. Caudal-motor volume in PD patients was significantly
reduced compared to controls. *pBonferroni < 0.05.
A.R. Khan et al. NeuroImage: Clinical 21 (2019) 101597
6
correlations, and associated p values contrasting OFF and ON Sessions
separately for PD patients and healthy controls are presented in Table 2,
demonstrating high test-retest reliability for all of our measures. Given
this high convergence between OFF and ON sessions, for the analyses
that follow, between-session average estimates were employed.
3.3. Total striatal, nucleus accumbens, caudate nucleus, and putamen
volumes
We observed no Group differences in comparing volume estimates
of total striatum (t≈0, pBonferroni≈0.999, BF10= 0.441), nucleus ac-
cumbens (t≈0, pBonferroni≈0.999, BF10= 0.366), caudate nuclei
(t≈0, pBonferroni≈0.999, BF10= 0.249), and putamen (t=0.025,
pBonferroni=0.980, BF10= 0.605).
3.4. Sub-regional striatal volume measures: PD vs. control
Between group t-tests were performed on normalized volume for
each of the seven sub-striatal regions. For the caudal-motor striatal sub-
region, the difference was significant (t=2.24, pBonferroni=0.029,
BF10= 21.965) reflecting atrophy for PD patients relative to controls
(Fig. 3).
3.5. Sub-regional displacement measures: PD vs. control
Between group t-tests were performed on surface displacement
measures for each of the seven sub-striatal regions. The executive
striatal sub-region was significantly inwardly displaced compared to
controls (t=2.20, pBonferroni=0.031, BF10= 8.481). The caudal-motor
and rostral-motor sub-regions were both trending toward being sig-
nificantly inwardly displaced compared to controls (t=1.98,
pBonferroni=0.051, BF10= 5.626, and t=1.71, pBonferroni=0.092,
BF10= 3.508 respectively). No other contrasts were significant.
3.6. FA of white matter projections to striatal sub-regions: PD vs. control
Between-group t-tests were performed on FA measures to each of
the seven striatal sub-regions. There were significant differences be-
tween PD patients and healthy controls in the caudal-motor (t=2.02,
pBonferroni=0.047, BF10= 6.132), temporal (t=3.41,
pBonferroni=0.001, BF10= 126.711), and trending in the executive sub-
region (t=1.92, pBonferroni=0.058, BF10= 5.167). In all cases, the FA
was decreased for PD patients relative to controls.
3.7. Sub-regional striatal volume measures: within PD group
Within the PD group, we examined the effect of disease stage, es-
timated by UPDRS-III scores in the OFF state on total and sub-regional
striatum volumes. The effect of disease stage was not significant on total
striatum volume, F < 1. UPDRS in the OFF state negatively correlated
with volume of the limbic striatum (r=−0.614 t=3.06,
pBonferroni=0.005; Fig. 4). That is, limbic striatum volume was lower for
patients with more advanced PD based on UPDRS-III scores. Correla-
tions on volume estimates in all other striatal sub-regions were not
significantly related to measures of disease stage.
4. Discussion
We segmented the striatum into seven functional regions based on
reciprocal connections to cortical areas as proposed by Tziortzi et al.
(2011; 2014). These consisted of caudal-motor, limbic, rostral-motor,
executive, parietal, occipital, and temporal sub-regions. Estimates of
volume, surface displacement relative to an average control-group
template, and FA of white matter tracts between the ON and OFF
medication sessions for each of the seven striatal sub-regions were
highly consistent.
When total volumes of striatum, nucleus accumbens, caudate nuclei,
and putamen were compared between PD patients and controls, no
differences arose. In contrast, volume was reduced, surface was dis-
placed inward, and white-matter connections were degraded for the
caudal-motor striatal sub-region in PD patients compared to controls.
Comparing PD patients to controls, inward surface displacement was
also noted in the executive striatal sub-region, and FA, our measure of
white-matter integrity, was reduced in executive and temporal striatal
sub-regions. All differences were significant even after correcting for
multiple comparisons. Further, all results were confirmed with
Bayesian analysis.
PD patients were examined separately, exploring the effect of motor
symptom severity, on striatal sub-regional volumes. The motor sub-
scale of the UPDRS is an objective assessment of disease severity that
accounts for significantly variable rates of disease progression across PD
patients (Stebbins, 1999). UPDRS-III score significantly, negatively
correlated with limbic striatum volume.
4.1. Striatal structural measures to diagnose PD
To date, there are no neuroimaging biomarkers that reliably detect
the presence of PD, allowing accurate diagnosis and appropriate en-
rollment of patients in investigations of disease-modifying therapies
(Tuite, 2016; Miller & O'Callaghan, 2015). In line with a number of
previous investigations, especially when considering small samples of
PD patients and healthy controls (Al-Radaideh & Rababah, 2016;
Menke et al., 2014; Lee et al., 2014), there were no significant between-
group differences in total striatum, nucleus accumbens, caudate nuclei,
or putamen volumes, all p > 0.900. At first glance, this seems sur-
prising given that the striatum is the central structure that is dopamine
deprived in PD. Looking more closely, there is variability across sub-
regions of the striatum in terms of how significantly and at what time
they are dopamine depleted in PD. Segmenting the striatum on the basis
of reciprocal connections to distinct cortical regions that are associated
with different functions, using a method outlined by Tziortzi et al.
(2011; 2014) we found significant atrophy and reduced structural
connectivity in the caudal-motor sub-region for PD patients relative to
healthy controls. This sub-region is notable because it is the first and
most dopamine-depleted striatal region in PD, mediating onset of motor
symptoms and hence signalling PD diagnosis (Kish et al., 1988). This
region is expected to be affected in all PD patients irrespective of dis-
ease stage. In addition to a biochemical deficit, structural disruptions in
the substrate of the striatum are expected to include intra-neuronal
alpha-synuclein accumulation (i.e., Lewy bodies) and neuronal loss
Fig. 4. Correlations between mean percentage of limbic striatum and UPDRS-III
in the OFF state.
Correlation between volume of limbic striatum in mm3 and UPDRS-III score in
the OFF state. Limbic striatum volume significantly, negatively correlated with
UPDRS-III score of PD patients tested in the OFF state.
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(Fahn, 2003). Evidence suggests cell-to-cell Lewy body propagation
through functional synapses (Calo et al., 2016). This presents a me-
chanism by which striatal sub-regional structural changes arise and
subsequently a means by which cortical regions are affected by disease
through white matter connections. FA, indexing integrity and density of
white matter projections, seemed even more sensitive in distinguishing
PD patients from controls, revealing impoverished white matter pro-
jections between cortex and caudal-motor, as well as between cortical
regions and executive, and temporal striatal regions for PD patients
relative to controls. Disruption of white matter connections potentially
precedes neuronal or gray matter loss, explaining the greater sensitivity
to earlier changes. These findings are further in line with the increas-
ingly supported view that dysfunction across widespread networks
occur in PD and underlie symptoms (Dang et al., 2012; Baggio et al.,
2015).
4.2. Structural biomarkers indicating PD stage
Biomarkers sensitive to the stage of PD are critically needed, pro-
viding objective endpoints for evaluating potential disease-modifying
therapies, yet, to this point, they are lacking (Tuite, 2016; Miller &
O'Callaghan, 2015). Clinico-pathological studies suggest that dopa-
mine-producing neurons in SNc and VTA are affected at different times
in disease progression, with VTA degeneration arising at much later
disease stages and to a lesser degree than SNc. Our results show that of
the only striatal downstream target of VTA, the limbic striatum, en-
compassing the VS, was reduced in patients with more advanced PD
based on greater motor signs as assessed with the UPDRS-III in the OFF
state.
4.3. Conclusions
Sub-dividing the striatum into seven regions based on connectivity
to distinct cortical regions and functional differences, using a semi-
automatic pipeline which we have made freely-available, in PD patients
and age- and education-matched healthy controls, we uncovered
changes in volume, surface displacement, and white matter con-
nectivity measures that were highly sensitive to presence of PD. These
measures further were found to have high test-retest reliability—a re-
quired property of a biomarker of disease. We found, in our hetero-
geneous sample of PD patients compared to controls, that the caudal-
motor region of the striatum was significantly atrophied, estimated by
measures of both volume and shape. In contrast, global structural
measures of the striatum defined on gross appearance (i.e., total
striatum, nucleus accumbens, caudate nucleus, and putamen) were
entirely insensitive to these group differences, suggesting that MRI
structural measures have no role in PD diagnosis. These findings sug-
gest that focussing in on the segment of striatum that is earliest and
maximally dopamine deprived in PD, the caudal-motor striatal region,
could provide a sensitive diagnostic biomarker of PD. Quantity and
integrity of white matter connections to this sub segment of DS, as well
as to adjacent sub segments (i.e., executive and temporal), appeared to
be potentially even more sensitive to PD-control differences. Finally, in
our PD sample, reduction in volume of limbic striatum, the only striatal
region that is innervated by dopamine-producing neurons of the later-
degenerating VTA, negatively correlated with UPDRS-III score in the
OFF state, an objective measure of PD severity. In this way, we suggest
a role for MRI in PD management.
Future research should aim to explore the methods proposed in this
manuscript in a larger sample of PD patients who are selected and
stratified to represent different PD clinical subtypes, symptoms, and
disease stages. Alternations in different striatal sub-regions could yield
important neuroimaging indicators of PD as well as account for the
emergence of different symptoms across PD patients and disease evo-
lution.
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